The use of a cationic liposome formulation (DOTAP) mixed with a recombinant tumor-associated antigen to induce immune responses and protective immunity in mice

Journal of Immunotherapy

Volumn 21, Issue 3, 1998, Pages 158-169

  Bei, Roberto ^a,b   Guptill, Virginia ^a   Masuelli, Laura ^a,b   Kashmiri, S V S ^a   Muraro, Raffaella ^c   Frati, Luigi ^b   Schlom, Jeffrey ^a   Kantor, Judith ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c d Annunzio University   (Italy)

Author keywords

Baculovirus; Boost; Immunogenicity; Liposome; Recombinant human CEA

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKINE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; INTERLEUKIN 4; LIPOSOME; N [1 (2,3 DIOLEOYLOXY)PROPYL] N,N,N TRIMETHYLAMMONIUM METHYLSULFATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BACULOVIRUS; CANCER IMMUNOTHERAPY; CANCER TRANSPLANTATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; IMMUNE RESPONSE; IMMUNITY; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE;

EID: 0031921507     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199805000-00001     Document Type: Article

References (46)

1. Thompson JA, Grunert F, Zimmerman W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 1991;5:344-66.
2. Horan Hand P, Robbins PF, Salgaller ML, Poole DJ, Schlom J. Evaluation of human carcinoembryonic-antigen (CEA)-transduced and non-transduced murine tumors as potential targets for anti-CEA therapies. Cancer Immunol Immunother 1993;36:65-75.
3. Kantor J, Irvine K, Abrams S, Kaufman H, Di Pietro J, Schlom J. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst 1992;84:1084-91.
4. Irvine K, Kantor J, Schlom J. Comparison of a CEA-recombinant vaccinia virus, purified CEA and an anti-idiotype bearing the image of a CEA epitope in the treatment and prevention of CEA-expressing tumors. Vaccine Res 1993;2:79-94.
5. Fuchs C, Krapf F, Kern P, Hoferichter S, Jager W, Kalden JR. CEA-containing immune complexes in sera of patients with colorectal and breast cancer: analysis of complexed immunoglobulin classes. Cancer Immunol Immunother 1988;26:180-4.
6. Mavligit GM, Stuckey S. Colorectal carcinoma. Evidence for circulating CEA-anti-CEA complexes. Cancer 1983;42:146-9.
7. Collatz E, Von Kleist S, Burtin P. Further investigations of circulating antibodies in colorectal cancer patients: on the autoantigenicity of the carcinoembryonic antigen. Int J Cancer 1971;8:298-303.
8. Chester KA, Begent RH. Circulating immune complexes (CIC), carcinoembryonic antigen (CEA) and CIC containing CEA as markers for colorectal cancer. Clin Exp Immunol 1984;58:685-93.
9. Ura Y, Ochi Y, Hamazu M, Ishida M, Nakajima K, Watanabe T. Studies on circulating antibody against carcinoembryonic antigen (CEA) and CEA-like antigen in cancer patients. Cancer Lett 1985;24:283-95.
10. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995;87:982-90.
11. Foon KA, Chakrabarty M, John W, Sherratt A, Kohler H, Bhattacharya-Chatterjee M. Active immunity to the carcinoembryonic antigen (CEA) in patients treated with an anti-idiotype monoclonal antibody vaccine. In: Proceedings of the 95th Annual Meeting of the Society for Biological Therapy, Oct 26-20, 1994.
12. Conry RM, Saleh MN, Schlom J, LoBuglio AF. Breaking tolerance to carcinoembryonic antigen with a recombinant vaccinia virus vaccine in man. Proc Am Assoc Cancer Res 1995;36 (abstract 2930).
13. Conry RM, Saleh MN, Schlom J, LoBuglio AF. Human immune response to carcinoembryonic antigen tumor vaccines. Proceedings of the 10th Annual Meeting of the Society for Biological Therapy, Madison, WI: Society for Biological Therapy, 1995.
14. Fagerberg J, Samanci A, Yi Q, et al. Recombinant carcinoembryonic antigen and granulocyte-macrophage colony stimulating factor for active immunization of colorectal carcinoma patients. Proceedings of the 11 th Annual Meeting of the Society for Biological Therapy, Madison, WI: Society for Biological Therapy, 1996.
15. Fishbein GE, McClay E, Berd D, Mastrangelo MJ. A postsurgical adjuvant trial of CEA immunization in patients with Dukes C and D colorectal cancer: a pilot study. Vaccine Res 1992;1:123-8.
16. Bei R, Kantor J, Kashmiri SVS, Abrams S, Schlom J. Enhanced immune responses and anti-tumor activity by baculovirus recombinant carcinoembryonic antigen (CEA) in mice primed with the recombinant vaccinia CEA. J Immunother 1994;16:275-82.
17. Phillips NC, Loutfi A, Huang L, A-Kareem AM, Shibata HR, Baines MG. Clinical evaluation of liposomal tumor antigen vaccines in patients with stage-III melanoma. Cancer Detect Prev 1990;14:491-5.
18. Bergers JJ, Den Otter W, De Groot JW, et al. Reconstituted membranes of tumor cells (proteoliposomes) induce specific protection to murine lymphoma cells. Cancer Immunol Immunother 1992;34:233-40.
19. Bergers JJ, Den Otter W, Dullens HFJ, et al. Effect of immunomodulators on specific tumor immunity induced by liposomeencapsulated tumor-associated antigens. Int J Cancer 1994;56:721-6.
20. Steel G Jr, Ravikumar T, Ross D, King V, Wilson RE, Dodson T. Specific immunotherapy with butanol-extracted, tumor-associated antigens incorporated into liposomes. Surgery 1994;96:352-9.
21. Gregoriadis G. Immunological adjuvants: a role for liposomes. Immunol Today 1990;11:89-97.
22. Gregoriadis G. The immunological adjuvant and vaccine carrier properties of liposome. J Drug Targeting 1994;2:351-6.
23. Buiting AMJ, Van Rooijen N, Classen E. Liposomes as antigen carriers and adjuvants in vivo. Res Immunol 1992;143:541-8.
24. Wassef NM, Alving CR, Richards RL. Liposomes as carrier for vaccines. Immunomethods 1994;4:217-22.
25. Gluck R. Liposomal presentation of antigens for human vaccines. Pharm Biotechnol 1995;6:325-45.
26. Allison AG, Gregoriadis G. Liposomes as immunological adjuvants. Nature 1974;252:252.
27. Alving OR. Liposomes as carriers of antigen and adjuvants. J Immunol Methods 1991;140:1-13.
28. Walker C, Selby M, Erickson A, Cataldo D, Valensi J-P, Van Nest G. Cationic lipids direct a viral glycoprotein into the class I major histocompatibility complex antigen-presentation pathway. Proc Natl Acad Sci USA 1992;89:7915-18.
29. Robbins PF, Kantor JA, Salgaller M, Hand PH, Fernsten PD, Schlom J. Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res 1991;51:3657-62.
30. Salgaller ML, Bei R, Schlom J, Poole DJ, Robbins PF. Baculovirus recombinants expressing the human carcinoembryonic antigen. Cancer Res 1993;53:2154-61.
31. Bei R, Kantor J, Kashmiri SVS, Schlom J. Serological and biochemical characterization of recombinant baculovirus carcinoembryonic antigen. Mol Immunol 1994;31:771-80.
32. McLaughlin J, Schlom J, Kantor J, Greiner JW. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2. Cancer Res 1996;56:2361-7.
33. Muraro R, Wunderlich D, Thor A, et al. Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues. Cancer Res 1985;45:5769-80.
34. Phillips NC, Emili A. Enhanced antibody to lyposome-associated protein antigens: preferential stimulation of IgG2a/b production. Vaccine 1992;10:151-8.
35. Shek PN, Sabiston BH. Immune response mediated by liposomeassociated protein antigens. II. Comparison of the effectiveness of vesicle-entrapped and surface-associated antigen in immunopotentiation. Immunology 1982;47:627-32.
36. Vannier WE, Snyder SL. Antibody responses to liposomeassociated antigen. Immunol Lett 1988;19:59-64.
37. Mitchell GF. The way ahead for vaccines and vaccination: symposium summary. Vaccine 1988;6:200-5.
38. Ada GL. What to expect of a good vaccine and how to achieve it. Vaccine 1988;6:77-9.
39. Edelman R, Tacket CO. Adjuvants. Intern Rev Immunol 1990;7:51-66.
40. Gregoriadis G, Florence AT. Liposome in drug delivery: clinical, diagnostic and ophthalmic potential. Drug 1993;45:15-28.
41. MacLachlan G, Davidson H, Davidson D, Dickinson P, Dorin J, Porteous D. DOTAP as a vehicle for efficient gene delivery in vitro and in vivo. Biochemica 1995;11:19-21.
42. Shahum E, Therien H-M. Correlation between in vitro and in vivo behaviour of liposomal antigens. Vaccine 1994;12:1125-31.
43. Verma JN, Rao M, Amselem S, et al. Adjuvant effects of liposomes containing lipid A: enhancement of liposomal antigen presentation and recruitment of macrophages. Infect Immun 1992;60:2438-44.
44. Kipps TJ, Parham P, Punt J, Herzenberg LA. Importance of immunoglobulin isotype in human antibody, cell mediated cytotoxicity directed by murine monoclonal antibodies. J Exp Med 1985;161:1-17.
45. Herlyn D, Herlyn M, Steplewski Z, Koprowsky H. Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma. Eur J Immunol 1979;9:657-9.
46. Feigner PL, Gadek TR, Holm M, et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 1987;84:7413-7.